| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Denosumab |
| Brand | Prolia® |
| Indication | For the Prevention of Osteoporotic Fractures in Postmenopausal Women |
| Assessment Process | |
| Rapid review commissioned | 27/05/2010 |
| Rapid review completed | 01/07/2010 |
| Rapid review outcome | We consider denosumab a cost-effective therapy for the prevention of osteoporotic fractures in postmenopausal women in the Irish healthcare setting |